Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

NCT02372578 PHASE2 TERMINATED

The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and tolerability of ASP3662 relative to placebo. The analgesic effect is evaluated by measuring percent responders, change in daily worst pain score, change in average daily pain score, Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC).

Details

Lead sponsor	Astellas Pharma Global Development, Inc.
Phase	PHASE2
Status	TERMINATED
Enrolment	115
Start date	Wed May 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Painful Diabetic Peripheral Neuropathy (PDPN)

Interventions

• ASP3662
• pregabalin
• ASP3662 placebo
• pregabalin placebo

Countries

United States